|
|
|
|
|
The Niche
|
Stem Cell & Regenerative Med Newsletter
|
|
|
|
|
|
Weekly reads: CRISPR, FDA stem cell loss, pioneering AMD study, MS, Verve Therapeutics
|
|
|
|
The big news of the week was the big FDA stem cell in court by Judge Jesus Bernal here in California, who ruled in favor of a chain of stem cell clinics called Cell Surgical Network. The FDA had been seeking an injunction against the clinics. I believe the ruling was founded in part on at least three major scientific …
|
|
|
|
|
|
|
|
Judge drops a bomb on FDA in Cell Surgical Network stem cell clinic case
|
|
|
|
In a ruling that could turn FDA stem cell clinic oversight on its head, Federal District Court Judge Jesus Bernal last night ruled in favor of the stem cell clinic chain Cell Surgical Network and other defendants. The FDA had been seeking permanent injunction against them. Here's the court ruling. Drs. Mark Berman and Elliot Lander were also named in …
|
|
|
|
|
|
|
|
Fact-checking exosome therapy: costs, risks, & lack of data
|
|
|
|
Exosome therapy is a still-experimental cell therapy approach aimed at treating specific diseases using secretions from cells. It's novel since most attention on cell therapies has been given to using the actual cells themselves. In addition, this approach is a newer idea than using cells as the drug to treat diseases. Interestingly, the term "cell therapy" has evolved to include …
|
|
|
|
|
|
